{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pan LA"],"funding":["NCATS NIH HHS","NCRR NIH HHS","NIMH NIH HHS"],"pagination":["42-50"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10171090"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["174(1)"],"pubmed_abstract":["<h4>Objective</h4>Treatment-refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. At least 15% of cases of major depressive disorder remain refractory to treatment. The authors previously identified a young adult with treatment-refractory depression and multiple suicide attempts with an associated severe deficiency of CSF tetrahydrobiopterin, a critical cofactor for monoamine neurotransmitter synthesis. Treatment with sapropterin, a tetrahydrobiopterin analogue, led to dramatic and long-lasting remission of depression. This sentinel case led the authors to hypothesize that the incidence of metabolic abnormalities contributing to treatment-refractory depression is underrecognized.<h4>Method</h4>The authors conducted a case-control, target"],"journal":["The American journal of psychiatry"],"pubmed_title":["Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment-Refractory Depression and Suicidal Behavior."],"pmcid":["PMC10171090"],"funding_grant_id":["UL1 TR000005","UL1 RR024153","K23 MH082884"],"pubmed_authors":["Baca CA","Finegold DN","Rengasamy M","Dobrowolski SK","Vockley J","Naviaux RK","Perel J","Diler R","Brent DA","Hughes M","Segreti AM","Steinfeld R","Pan LA","Walano N","Zimmer T","Martin P","Kassiff S","McKain BW","Pasquino M","Hyland K","Peters DG"],"additional_accession":[]},"is_claimable":false,"name":"Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment-Refractory Depression and Suicidal Behavior.","description":"<h4>Objective</h4>Treatment-refractory depression is a devastating condition with significant morbidity, mortality, and societal cost. At least 15% of cases of major depressive disorder remain refractory to treatment. The authors previously identified a young adult with treatment-refractory depression and multiple suicide attempts with an associated severe deficiency of CSF tetrahydrobiopterin, a critical cofactor for monoamine neurotransmitter synthesis. Treatment with sapropterin, a tetrahydrobiopterin analogue, led to dramatic and long-lasting remission of depression. This sentinel case led the authors to hypothesize that the incidence of metabolic abnormalities contributing to treatment-refractory depression is underrecognized.<h4>Method</h4>The authors conducted a case-control, target","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jan","modification":"2025-04-21T22:44:00.083Z","creation":"2025-04-05T18:54:49.92Z"},"accession":"S-EPMC10171090","cross_references":{"pubmed":["27523499"],"doi":["10.1176/appi.ajp.2016.15111500"]}}